Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mersana Therapeutics, Inc. MRSN
$7.94
-$0.05 (-0.69%)
На 18:00, 12 мая 2023
+139.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
867643895.00000000
-
week52high
8.39
-
week52low
2.68
-
Revenue
26581000
-
P/E TTM
-3
-
Beta
1.73425600
-
EPS
-3.19000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:00
Описание компании
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 09 авг 2022 г. |
| Baird | Outperform | Outperform | 09 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 09 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 18 февр 2022 г. |
| HC Wainwright & Co. | Buy | 30 авг 2021 г. | |
| Truist Securities | Buy | 21 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Protopapas Anna | D | 48733 | 17346 | 17 янв 2023 г. |
| Yang Arvin | D | 30821 | 2209 | 17 янв 2023 г. |
| MISRA TUSHAR | D | 5930 | 458 | 17 янв 2023 г. |
| Mandelia Ashish | D | 13619 | 3575 | 17 янв 2023 г. |
| Lowinger Timothy B | D | 180363 | 6233 | 17 янв 2023 г. |
| DeSchuytner Brian | D | 32781 | 5131 | 17 янв 2023 г. |
| Carvajal Alejandra | D | 11020 | 782 | 17 янв 2023 г. |
| Protopapas Anna | D | 17708 | 17708 | 15 янв 2023 г. |
| Protopapas Anna | D | 42500 | 21250 | 15 янв 2023 г. |
| Protopapas Anna | A | 66079 | 17708 | 15 янв 2023 г. |
Новостная лента
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
GlobeNewsWire
03 мая 2023 г. в 08:00
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time.
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
GlobeNewsWire
02 мая 2023 г. в 08:00
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight
Seeking Alpha
03 апр 2023 г. в 17:20
Concerns related to safety risks around ILD/pneumonitis are overblown in a disease of high unmet needs. I believe clinical benefits outweigh potential safety overhang, and key studies have put in the necessary steps to mitigate ILD risks.
Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Call Transcript
Seeking Alpha
28 февр 2023 г. в 10:50
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Jason Fredette - SVP, IR and Corporate Communications Anna Protopapas - President and CEO Arvin Yang - Chief Medical Officer Brian DeSchuytner - CFO Conference Call Participants Jonathan Chang - SVB Securities Ashiq Mubarack - Citi Asthika Goonewardene - Truist Securities Boris Peaker - Cowen Operator Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode.
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
GlobeNewsWire
21 февр 2023 г. в 08:00
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.